Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess Long Term Persistence of a Primary Dose of GSK Biologicals' Meningococcal Vaccine 134612 Versus One Dose of Mencevax™ ACWY in Healthy Adolescents/Young Adults (15 to 19 Years at Vaccination)

NCT00390143 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00390143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess Long Term Persistence of a Primary Dose of GSK Biologicals' Meningococcal Vaccine 134612 Versus One Dose of Mencevax™ ACWY in Healthy Adolescents/Young Adults (15 to 19 Years at Vaccination)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
May 31, 2009
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal